临床试验 以下为当前的临床试验。117 研究 神经科 (仅限仍在招募的研究). 按院区、状态和其他条件筛选该研究列表。 Brain Tumor Repository Scottsdale/Phoenix, Ariz. The main objective of the Brain Tumor Repository is to allow access to coded patient data by researchers both inside and outside of the Mayo Clinic system so that important research questions can be answered. Detection of Vascular and Inflammatory Plasma Biomarkers in Patients Diagnosed with Obstructive Sleep Apnea and MRI-defined Cerebral Small Vessel Disease Jacksonville, Fla. The purpose of this study is to evaluate plasma biomarkers of vascular function and inflammation in patients with newly-diagnosed Obstructive Sleep Apnea (OSA) and pre-existing imaging evidence of Cerebral Small Vessel Disease (CSVD). Image-based Mapping of Brain Tumors Scottsdale/Phoenix, Ariz., Rochester, Minn. The purpose of this study is to combine MRI images with histologic and genetic analysis of cancer (from blood and tissue samples) to improve the overall accuracy of diagnosis and effectiveness of cancer treatment. A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients with Recurrent Glioblastoma with Elevated Mutational Burden Jacksonville, Fla., Rochester, Minn., La Crosse, Wis., Scottsdale/Phoenix, Ariz., Eau Claire, Wis. The purpose of this study is to evaluate the effect of immunotherapy drugs (ipilimumab and nivolumab) in treating patients with glioblastoma that has come back (recurrent) and carries a high number of mutations. Cancer is caused by changes (mutations) to genes that control the way cells function. Tumors with high number of mutations may respond well to immunotherapy. Immunotherapy with monoclonal antibodies such as ipilimumab and nivolumab may help the body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Giving ipilimumab and nivolumab may lower the chance of recurrent glioblastoma with high number of mutations from growing or spreading compared to usual care (surgery or chemotherapy). Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study) Jacksonville, Fla., Scottsdale/Phoenix, Ariz. The purose of this study is to evaluate the effiectiveness, safety, and pharmacokinetics of tirabrutinib monotherapy in patients with relapsed or refractory Primary Central Nervous System Lymphoma PCNSL (Part A), and tirabrutinib in combination with one of two different high dose methotrexate based regimens (methotrexate/ temozolimide/rituximab or rituximab/methotrexate/procarbazine/ vincristine) as first line therapy in patients with newly diagnosed, treatment naïve PCNSL (Part B). Mayo Clinic is only participatin gin Part B, and only in the MTR regimen. Metastatic Tumor Research and Outcomes Network Rochester, Minn. The registry aims to collect patient information such as patient demographics, co-morbidities, clinical, diagnostic, and therapeutic data, as well as information on adverse events and HRQOL outcomes specific for patients with metastatic spine tumor(s). Electrophysiological Biomarkers for Parkinson's Disease Scottsdale/Phoenix, Ariz. This study will determine the validity of predictive and surrogate biomarkers for the detection of Parkinson's disease and Parkinson's disease cognitive decline. Brain Health and Dementia Prevention Registry Jacksonville, Fla. The purpose of this study is to create a registry of patients having a clinical diagnosis and collect demographics, cognitive testing, blood and cerebrospinal fluid so that biomarkers and genetic difference can be found in different patient groups. Inherited Muscle Diseases Repository Rochester, Minn. To establish a repository of DNA samples collected prospectively from patients with inherited myopathies of unknown molecular and/or biochemical defect. To access residual muscle specimens from diagnostic muscle biopsies obtained as part of the routine medical care. The biospecimens will be used to better understanding the underlying molecular defects and mechanisms of muscle diseases. A Study of Nivolumab and Multi-fraction Stereotactic Radiosurgery with or without Ipilimumab in Treating Participants with Recurrent Grade II-III Meningioma Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz. The purpose of this study is to evaluate the side effects and best dose of nivolumab when given together with multi-fraction stereotactic radiosurgery and to see how well they work with or without ipilimumab in treating participants with grade II-III meningioma that has come back. Monoclonal antibodies, such as nivolumab and ipilimumab, may interfere with the ability of tumor cells to grow and spread. Stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may cause less damage to normal tissue. It is not yet known whether giving nivolumab and multi-fraction stereotactic radiosurgery with or without ipilimumab may work better in treating participants with grade II-III meningioma. Pagination 临床研究 PrevPrevious Page Go to page 77 Go to page 88 Go to page 99 Go to page 1010 Go to page 1111 NextNext Page 以下为当前的临床试验。117 研究 神经科 (仅限仍在招募的研究). 按院区、状态和其他条件筛选该研究列表。 Brain Tumor Repository Scottsdale/Phoenix, Ariz. The main objective of the Brain Tumor Repository is to allow access to coded patient data by researchers both inside and outside of the Mayo Clinic system so that important research questions can be answered. Detection of Vascular and Inflammatory Plasma Biomarkers in Patients Diagnosed with Obstructive Sleep Apnea and MRI-defined Cerebral Small Vessel Disease Jacksonville, Fla. The purpose of this study is to evaluate plasma biomarkers of vascular function and inflammation in patients with newly-diagnosed Obstructive Sleep Apnea (OSA) and pre-existing imaging evidence of Cerebral Small Vessel Disease (CSVD). Image-based Mapping of Brain Tumors Scottsdale/Phoenix, Ariz., Rochester, Minn. The purpose of this study is to combine MRI images with histologic and genetic analysis of cancer (from blood and tissue samples) to improve the overall accuracy of diagnosis and effectiveness of cancer treatment. A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients with Recurrent Glioblastoma with Elevated Mutational Burden Jacksonville, Fla., Rochester, Minn., La Crosse, Wis., Scottsdale/Phoenix, Ariz., Eau Claire, Wis. The purpose of this study is to evaluate the effect of immunotherapy drugs (ipilimumab and nivolumab) in treating patients with glioblastoma that has come back (recurrent) and carries a high number of mutations. Cancer is caused by changes (mutations) to genes that control the way cells function. Tumors with high number of mutations may respond well to immunotherapy. Immunotherapy with monoclonal antibodies such as ipilimumab and nivolumab may help the body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Giving ipilimumab and nivolumab may lower the chance of recurrent glioblastoma with high number of mutations from growing or spreading compared to usual care (surgery or chemotherapy). Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study) Jacksonville, Fla., Scottsdale/Phoenix, Ariz. The purose of this study is to evaluate the effiectiveness, safety, and pharmacokinetics of tirabrutinib monotherapy in patients with relapsed or refractory Primary Central Nervous System Lymphoma PCNSL (Part A), and tirabrutinib in combination with one of two different high dose methotrexate based regimens (methotrexate/ temozolimide/rituximab or rituximab/methotrexate/procarbazine/ vincristine) as first line therapy in patients with newly diagnosed, treatment naïve PCNSL (Part B). Mayo Clinic is only participatin gin Part B, and only in the MTR regimen. Metastatic Tumor Research and Outcomes Network Rochester, Minn. The registry aims to collect patient information such as patient demographics, co-morbidities, clinical, diagnostic, and therapeutic data, as well as information on adverse events and HRQOL outcomes specific for patients with metastatic spine tumor(s). Electrophysiological Biomarkers for Parkinson's Disease Scottsdale/Phoenix, Ariz. This study will determine the validity of predictive and surrogate biomarkers for the detection of Parkinson's disease and Parkinson's disease cognitive decline. A Study Evaluating the Use of 48-hour Ambulatory EEG Monitoring in Early Onset Alzheimer’s Disease Jacksonville, Fla. The purpose of this study is to characterize and study the relationship of the clinical risk factors and predictors of seizures and epilepsy in patients with Early Onset Alzheimer's Disease (EOAD) using a 48-hour CAA-EEG. Brain Health and Dementia Prevention Registry Jacksonville, Fla. The purpose of this study is to create a registry of patients having a clinical diagnosis and collect demographics, cognitive testing, blood and cerebrospinal fluid so that biomarkers and genetic difference can be found in different patient groups. Inherited Muscle Diseases Repository Rochester, Minn. To establish a repository of DNA samples collected prospectively from patients with inherited myopathies of unknown molecular and/or biochemical defect. To access residual muscle specimens from diagnostic muscle biopsies obtained as part of the routine medical care. The biospecimens will be used to better understanding the underlying molecular defects and mechanisms of muscle diseases. Pagination 临床研究 PrevPrevious Page Go to page 77 Go to page 88 Go to page 99 Go to page 1010 Go to page 1111 NextNext Page 申请预约 专长与排名研究 June 19, 2024 Share on: FacebookTwitterWeChatWeChatCloseWeibo 妙佑医疗国际明尼苏达州罗切斯特院区、妙佑医疗国际佛罗里达州杰克逊维尔院区和妙佑医疗国际亚利桑那州凤凰城/斯科茨代尔院区均在《美国新闻与世界报道》2024 - 2025 最佳神经内科和神经外科医院评选中名列前茅。 了解更多关于这一最高荣誉的信息 神经科科室首页部分概述测试与程序主治医生专业团队专长与排名临床试验研究患者故事费用与保险Mayo Clinic 新闻转诊 研究完全以患者为中心。 请参见副本 供视频使用 研究完全以患者为中心。 [音乐播放] 妙佑医疗国际神经学教授 Joseph Sirven 医学博士:妙佑医疗的使命以患者为中心。患者第一。我们的使命和研究是为了更好地帮助患者,提供以患者为中心的护理。在很多方面,这是一个循环。这个过程可能很简单,就是先在实验室里出现一个想法,然后带到病床旁加以实施,如果一切顺利,对患者有所助益, 就形成标准。我认为这就是妙佑医疗国际研究方法的一个独特之处,而这种以患者为中心的方式,也是妙佑医疗在众多医疗机构中脱颖而出的原因之一。 部分预约门诊概述测试与程序主治医生专业团队专长与排名临床试验研究患者故事费用与保险Mayo Clinic 新闻转诊 ORG-20117054 医学科室与中心 神经科